BACE-1 inhibitor
Showing 1 - 25 of >10,000
NSCLC Trial (Drug-eluting beads bronchial arterial chemoembolization, Programmed Cell Death Protein 1 Inhibitor)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Drug-eluting beads bronchial arterial chemoembolization
- Programmed Cell Death Protein 1 Inhibitor
- (no location specified)
Feb 17, 2022
NSCLC Trial in China (PD-1 Antibody, BACE)
Recruiting
- NSCLC
- PD-1 Antibody
- BACE
-
Guiyang, Guizhou, China
- +7 more
Nov 8, 2022
Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)
Not yet recruiting
- Metastatic Colorectal Cancer
- (no location specified)
Oct 31, 2023
Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)
Completed
- Advanced Solid Tumor
- Inosine 0.2g orally 3 times/day
- PD-1/PD-L1 inhibitor ,chemotherapy/targeting
-
Beijing, Beijing, ChinaQin li
Mar 30, 2023
Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)
Recruiting
- Nasopharyngeal Carcinoma
- Anti-EGFR and PD-1 inhibitor arm
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Chemo-Induced Thrombocytopenia Trial (Hetrombopag)
Not yet recruiting
- Chemotherapy-Induced Thrombocytopenia
- (no location specified)
Jul 24, 2023
Head Neck Cancer, Intratumoral Injection Trial in Chicago (RiMO-301)
Recruiting
- Head Neck Cancer
- Intratumoral Injection
-
Chicago, IllinoisUniversity of Illinois at Chicago
Apr 28, 2023
NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Alirocumab and Cemiplimab
- (no location specified)
Jan 31, 2023
Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)
Not yet recruiting
- Metastatic Microsatellite-stable Colorectal Cancer
- (no location specified)
Sep 1, 2023
Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Tumors Trial in Guangzhou (Pemigatinib, PD-1 Inhibitors)
Recruiting
- Carcinoma
- +4 more
- Pemigatinib
- PD-1 Inhibitors
-
Guangzhou, Guangdong, ChinaLei Zhang
Jun 21, 2023
Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,
Completed
- Gastrointestinal Tumor
- Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
- tislelizumab (BeiGene, China) combined with PD-1 inhibitor
-
Hangzhou, ChinaZhejiang Hospital
Sep 1, 2023
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and
Not yet recruiting
- Colorectal Neoplasms
-
Beijing, Xicheng Dis, ChinaBeijing Friendship Hospital, Capital medical University
Sep 5, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Dalpiciclib Isetionate Tablets, Camrelizumab
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023
Esophageal Tumor Metastatic, Esophageal Cancer Stage IVb Trial in Beijing (drug, biological, radiation)
Recruiting
- Esophageal Neoplasm Metastatic
- Esophageal Cancer Stage IVb
- TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
- +3 more
-
Beijing, Beijing, ChinaCancer hospital, CAMS
Oct 19, 2023
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Radiotherapy
- +4 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),
Not yet recruiting
- Nasopharyngeal Carcinoma
- Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Neoadjuvant Therapy
- 3cycles (Toripalimab + cetuximab)
- +2 more
-
Wuhan, Hebei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023
Oropharyngeal Cancer Trial in Shanghai (Toxicities reduced treatment, Conventional treatment)
Recruiting
- Oropharyngeal Cancer
- Toxicities reduced treatment
- Conventional treatment
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound
Active, not recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Albumin-bound Paclitaxel
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023
HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With
Not yet recruiting
- Gastric Cancer
- Observational
- (no location specified)
Dec 13, 2022
Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)
Not yet recruiting
- Hepatocellular Carcinoma
- iNKT Cells
- +2 more
-
Beijing, Beijing, ChinaBeijing Youan Hospital,Capital Medical University
Jul 24, 2023
Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,
Not yet recruiting
- Advanced Lung Squamous Cell Carcinoma
- low-dose radiation therapy and stereotactic body radiation therapy
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Nov 13, 2023